{
    "nct_id": "NCT03132922",
    "official_title": "Phase 1 Dose Escalation, Multi-tumor Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered MAGE-A4ᶜ¹º³²T in HLA-A2+ Subjects With MAGE-A4 Positive Tumors",
    "inclusion_criteria": "1. Subject is ≥18 to 75 years of age at the time of signing the study informed consent.\n2. Subject has histologically confirmed diagnosis of any one of the indicated tumor types\n3. Subject is HLA-A*02 positive. (This determination will be made under screening protocol ADP-0000-001).\n4. Subject's tumor shows expression of the MAGE-A4 RNA or protein. (This determination will be made under screening protocol ADP-0000-001).\n5. Adequate organ function as indicated in the study protocol\n6. Subject has measurable disease according to RECIST v1.1 criteria prior to lymphodepletion\n7. Subject meets disease-specific requirements per protocol\n\n7. Subject has anticipated life expectancy > 6 months prior to leukapheresis and >3 months prior to lymphodepletion.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 75 Years",
    "exclusion_criteria": "1. Subject does not express appropriate HLA-A genotype\n2. Subject is receiving excluded therapy/treatment per protocol\n3. Subject has symptomatic CNS metastases.\n4. Subject has any other active malignancy besides the tumor under study within 3 years prior to Screening. Subject has uncontrolled intercurrent illness.\n5. Subject has active infection with HIV, HBV, HCV or HTLV\n6. Subject is pregnant or breastfeeding.\n\nAdditional Exclusion Criteria for the Radiation Substudy:\n\n* Subject does not meet eligibility criteria for the main study (ADP-0044-001).\n* Subject does not have at least one target lesion amenable to radiation.\n* Certain radiation therapy within 6 months of clinical trial are an exclusion.\n* Metastatic disease impinging on the spinal cord or threatening spinal cord compression.",
    "miscellaneous_criteria": ""
}